Association of neuropeptide Y (NPY), interleukin-1B (IL1B) genetic variants and correlation of IL1B transcript levels with vitiligo susceptibility

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Laddha, Naresh C ^a   Dwivedi, Mitesh ^a   Mansuri, Mohmmad Shoab ^a   Singh, Mala ^a   Patel, Hetanshi H ^a   Agarwal, Nishtha ^a   Shah, Anish M ^a   Begum, Rasheedunnisa ^a  

^a M S UNIVERSITY OF BARODA   (India)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1BETA; NEUROPEPTIDE Y; MESSENGER RNA;

ALLELE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; EXON; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HAPLOTYPE; HUMAN; IL1B GENE; INDIA; MAJOR CLINICAL STUDY; MALE; NPY GENE; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; TREND STUDY; VITILIGO; GENETIC PREDISPOSITION; GENETICS; METABOLISM; POLYMERASE CHAIN REACTION; SEX DIFFERENCE;

EXONS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INDIA; INTERLEUKIN-1BETA; LINKAGE DISEQUILIBRIUM; MALE; NEUROPEPTIDE Y; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; SEX FACTORS; VITILIGO;

EID: 84907143747     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107020     Document Type: Article

References (73)

1. Alkhateeb A, Fain P, Thody A, Bennett DC, Spritz RA (2003) Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families. Pigment Cell Res 16: 208-214.
2. Shajil EM, Agrawal D, Vagadia K, Marfatia YS, Begum R, et al. (2006) Vitiligo: Clinical profiles in Vadodara, Gujarat. Ind J Dermatol 51: 100-104.
3. Glassman SJ (2011) Vitiligo: Reactive Oxygen Species and T-Cells. Clin Sci Lond 120: 99-120.
4. Shajil EM, Chatterjee S, Agrawal D, Bagchi T, Begum R (2006) Vitiligo: pathomechanisms and genetic polymorphism of susceptible genes. Indian J Exp Biol 44: 526-539.
5. Morrone A, Picardo M, De Luca C, Terminali O, Passi S, et al. (1992) Catecholamines and vitiligo. Pigment Cell Res 5: 65-69.
6. Rozengurt E (1995) Convergent Signalling in the action of integrins, neuropeptides, growth factors and oncogenes. Cancer Surv 24: 81-96.
7. Prod'homme T, Weber MS, Steinman L, Zamvil SS (2006) A neuropeptidemediated inflammation, Y? Trends Immunol 27: 164-167.
8. Schwanstecher M (2011) Diabetes-Perspectives in Drug Therapy, Handbook of Experimental Pharmacology. Springer 410p.
9. Joana RS, Ines MA, Ana Rita A, Mandes AF, Ferreira L, et al. (2009) Regulation of catecholamine release and tyrosine hydroxylase in human adrenal chromaffin cells by interleukin-1β: role of neuropeptide Y and nitric oxide. J Neurochem 109: 911-922.
10. Wheway J, Mackay CR, Newton RA, Sainsbury A, Boey D, et al. (2005) A fundamental bimodal role for neuropeptide Y1 receptor in the immune system. J Exp Med 202: 1527-1538.
11. Bedoui S, Miyake S, Straub RH, Horsten SV, Yamamura T, et al. (2004) More sympathy for autoimmunity with neuropeptide Y? Trends Immunol 25: 508-512.
12. Liu P, Bondesson L, Loentz W, Jonansson O (1996) The occurrence of cutaneous nerve endings and neuropeptides in vitiligo vulgaris: a case control study. Arch Dermatol Res 288: 670-675.
13. Tu C, Zhao D, Lin X (2001) Levels of neuropeptide-Y in the plasma and skin tissue fluids of patients with vitiligo. J Dermatol Sci 27: 178-182.
14. Mahé Y, Oppenheim J (1992) Interleukin 1. In: Roitt, IM and Delves, PJ, editors Encycloepedia of Immunology, Harcourt Brace Jovanovich, Sandiego, pp. 897-901.
15. Bendtzen K (1998) Interleukin-1, Interleukin-6 and tumor necrosis factor in infection, inflammation and immunity. Immunol Lett 19: 183-192.
16. De Sanctis JB, Blanca I, Bianco NE (1997) Secretion of cytokines by natural killer cells primed with interleukin-2 and stimulated with different lipoproteins. Immunology 90: 526-533.
17. Sommer W, Lidstrom J, Sun H, Passer D, Eskay R, et al. (2010) Human NPY Promoter Variation rs16147: T>C as a Moderator of Prefrontal NPY Gene Expression and Negative Affect. Hum Mutat 31: 1594-1608.
18. Alyssa K, Robert M, Vincent B, Christopher C, Gonzalez RD, et al. (2008) A Broad Analysis of IL1 Polymorphism and Rheumatoid Arthritis. Arthritis Rheum 58: 1947-1957.
19. Barrett J, Fry B, Maller J, Dally M (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21: 263-265.
20. Shi Y, He L (2005) SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res 15: 97-98.
21. Silver DL, Pavan WJ (2006) The Origin and Development of Neural Crest-Derived Melanocytes. In: Hearing VJ, Leong SPL, editors. From Melanocytes to Malanoma. Humana Press Inc. pp3-26.
22. Iyenger B (1989) Modulation of melanocytic activity by acetylcholine. Acta Anat (Basel) 136: 139-41.
23. Shajil EM, Marfatia YS, Begum R (2006) Acetylcholine esterase levels in different clinical types of vitiligo in Baroda, Gujarat. Ind J Dermatol 51: 289-291.
24. Kallio J, Pesonen U, Kaipio K, Karvonen MK, Jaakkola U, et al. (2001) Altered intracellular processing and release of neuropeptide Y due to leucine 7 to proline 7 polymorphism in the signal peptide of preproneuropeptide Y in humans. FASEB J 15: 1242-1244.
25. Ma J, Nordman S, Möllsten A, Falhammer H, Brismar K, et al. (2007) Distribution of neuropeptide Y Leu7Pro polymorphism in patients with type 1 diabetes and diabetic nephropathy among Swedish and American populations. Eur J Endocrinol 157: 641-645.
26. Zhou Z, Zhu G, Hariri AR, Enoch MA, Scott D, et al. (2008) Genetic variation in human NPY expression affects stress response and emotion. Nature 452: 997-1001.
27. Dinarello CA, Donath MY, Mandrup-Poulsen T (2010) Role of IL-1beta in type 2 diabetes. Curr Opin Endocrinol Diabetes Obes 17: 314-321.
28. Solomon SS, Griffin WS, K O'Banion (2008) The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective. J Neuroinflam 5: 7.
29. Al Abadie M, Senior H, Bleehen S, Gawkrodgen D (1994) Neuropeptide and neuronal marker studies in vitiligo. Brit J Dermatol 131: 160-165.
30. Caixia T, Daming Z, Xiran L (2001) Levels of neuropeptide-Y in the plasma and skin tissue fluids of patients with vitiligo. J Dermatol Sci 27: 178-182.
31. Nussdorfer G, Malendowicz L (1998) Role of VIP, PACAP, and related peptides in the regulation of the hypothalamo-pituitary-adrenal axis. Peptides 19: 1443-1467.
32. Cavadas C, Silva A, Mosimann F, Cotrim M, Ribeiro C, et al. (2001) NPY regulates catecholamine secretion from human adrenal chromaffin cells. J Clin Endocrinol Metab 86: 5956-5963.
33. Kobayashi H, Yanagita T, Yokoo H, Wada A (2003) Pathophysiological function of adrenomedullin and proadrenomedullin N-terminal peptides in adrenal chromaffin cells. Hypertens Res 26: S71-78.
34. Ait-Ali D, Turquier V, Grumolato L, Yon L, Jourdain M, et al. (2004) The proinflammatory cytokines tumor necrosis factor-alpha and interleukin-1 stimulate neuropeptide gene transcription and secretion in adrenochromaffin cells via activation of extracellularly regulated kinase 1/2 and p38 protein kinases, and activator protein-1 transcription factors. Mol Endocrinol 18: 1721-1739.
35. Cavadas C, Cefai D, Rosmaninho-Salgado J, Vieira MA, Moura E, et al. (2006) Deletion of the (NPY) Y1 receptor gene reveals a regulatory role of neuropeptide Y on catecholamine synthesis and secretion. Proc Natl Acad Sci USA 103: 10497-10502.
36. Yen PM (2001) Physiological and molecular basis of thyroid hormone action. Physiol Rev 81: 1097-1142.
37. Simon JD, Peles D, Wakamatsu K, Ito S (2009) Current challenges in understanding melanogenesis: bridging chemistry, biological control, morphology and function. Pigment Cell Melanoma Res 22: 563-579.
38. Slominski A, Zmijewski MA, Pawelek J (2012) L-tyrosine and L-dihydroxyphenyl alanine as hormone-like regulators of melanocyte functions. Pigment Cell Melanoma Res 25: 14-27.
39. Pacher P, Beckman JS, Liaudet L (2007) Nitric oxide and peroxynitrite in health and disease. Physiol Rev 87: 315-424.
40. Hazneci E, Karabulut AB, Ozturk C, Batcioglu K, Dogan G, et al. (2005) A comparative study of superoxide dismutase, catalase, and glutathione peroxidase activities and nitrate levels in vitiligo patients. Int J Dermatol 44: 636-640.
41. Tsang AH, Chung KK (2009) Oxidative and nitrosative stress in Parkinson's disease. Biochim Biophys Acta 1792: 643-650.
42. Schallreuter KU, Salem MM, Hasse S, Rokos H (2011) The redox - biochemistry of human hair pigmentation. Pigment Cell Melanoma Res 24: 51-62.
43. McLane J, Osber M, Pawelek JM (1987) Phosphorylated isomers of L-dopa stimulate MSH binding capacity and responsiveness to MSH in cultured melanoma cells. Biochem Biophys Res Commun 145: 719-725.
44. Slominski A, Jastreboff P, Pawelek J (1989) L-tyrosine stimulates induction of tyrosinase activity by MSH and reduces cooperative interactions between MSH receptors in hamster melanoma cells. Biosci Rep 9: 579-586.
45. Slominski A, Tobin DJ, Shibahara S, Wortsman J (2004) Melanin pigmentation in mammalian skin and its hormonal regulation. Physiol Rev 84: 1155-1228.
46. Kemp EH, Waterman EA, Hawes BE, O'Neill K, Gottumukkala RV, et al. (2002) The melanin-concentrating hormone receptor 1, a novel target of autoantibody responses in vitiligo. J Clin Invest 109: 923-930.
47. Hoogduijn MJ, Ancans J, Suzuki I, Estdale S, Thody AJ (2002) Melaninconcentrating hormone and its receptor are expressed and functional in human skin. Biochem Biophys Res Commun 296: 698-701.
48. Slominski A, Wortsman J (2000) Neuroendocrinology of the skin. Endocr Rev 21: 457-487.
49. Slominski AT, Zmijewski MA, Skobowiat C, Zbytek B, Slominski RM, et al. (2012) Sensing the environment: regulation of local and global homeostasis by the skin's neuroendocrine system. Adv Anat Embryol Cell Biol 212: 1-115.
50. Slominski AT, Zmijewski MA, Zbytek B, Tobin DJ, Theoharides TC, et al. (2013) Key role of CRF in the skin stress response system. Endocr Rev Dec 34: 827-884.
51. Slominski A, Wortsman J, Luger T, Paus R, Solomon S (2000) Corticotropin releasing hormone and proopiomelanocortin involvement in the cutaneous response to stress. Physiol Rev 80: 979-1020.
52. Morita K, Dohi T, Kitayama S, Koyama Y, Tsujimoto A (1987) Enhancement of stimulation-evoked catecholamine release from cultured bovine adrenal chromaffin cells by forskolin. J Neurochem 48: 243-247.
53. Cox M, Parsons S (1997) Roles for protein kinase C and mitogen-activated protein kinase in nicotine-induced secretion from bovine adrenal chromaffin cells. J Neurochem 69: 1119-1130.
54. Laddha NC, Dwivedi M, Mansuri MS, Gani AR, Ansarullah M, et al. (2013) Vitiligo: interplay between oxidative stress and immune system. Exp Dermatol 22: 245-250.
55. Visner GA, Chesrown SE, Monnier J, Ryan US, Nick HS (1992) Regulation of manganese superoxide dismutase: IL-1 and TNF induction in pulmonary artery and microvascular endothelial cells. Biochem Biophys Res Commun 188: 453-462.
56. Laddha NC, Dwivedi M, Gani AR, Shajil EM, Begum R (2013) Involvement of Superoxide Dismutase Isoenzymes and their genetic variants in progression and higher susceptibility towards Vitiligo. Free Rad Biol Med 65: 1110-1125.
57. Hwang IR, Kodama T, Kikuchi S, Sakai K, Peterson LE, et al. (2002) Effect of interleukin 1 polymorphisms on gastric mucosal interleukin 1beta production in Helicobacter pylori infection. Gastroenterology 123: 1793-1803.
58. Hulkkonen J, Laippala P, Hurme M (2000) A rare allele combination of the interleukin-1 gene complex is associated with high interleukin-1 beta plasma levels in healthy individuals. Eur Cytokine Network 11: 251-255.
59. Dwivedi M, Laddha NC, Imran M, Shah BJ, Begum R (2011) Cytotoxic T lymphocyte associated antigen-4 (CTLA-4) in isolated vitiligo: a genotypephenotype correlation. Pigment Cell Melanoma Res 24: 737-740.
60. Singh A, Sharma P, Kar HK, Sharma VK, Tembhre MK, et al. (2012) HLA alleles and amino acid signatures of the peptide binding pockets of HLA molecules in Vitiligo. J Invest Dermatol 132: 124-134.
61. Birlea SA, Ahmad FJ, Uddin RM, Ahmad S, Begum R, et al. (2013) Association of Generalized Vitiligo with HLA Class II Loci in Patients from the Indian Subcontinent. J Invest Dermatol 133: 1369-1372.
62. Imran M, Laddha NC, Dwivedi M, Mansuri MS, Singh J, et al. (2012) Interleukin-4 genetic variants correlate with its transcript and protein levels in vitiligo patients. Brit J Dermatol 167: 314-323.
63. Laddha NC, Dwivedi M, Begum R (2012) Increased Tumor Necrosis Factor (TNF)-α and its promoter polymorphisms correlate with disease progression and higher susceptibility towards vitiligo. PLoS ONE 7: 12 e52298.
64. Laddha NC, Dwivedi M, Gani AR, Mansuri MS, Begum R (2013) Tumor Necrosis Factor B (TNFB) genetic variants and its increased expression are associated with vitiligo susceptibility. PLoS ONE 8: e81736.
65. Dwivedi M, Laddha NC, Shah K, Shah BJ, Begum R (2013) Involvement of Interferon-Gamma Genetic Variants and Intercellular Adhesion Molecule-1 in Disease Onset and Progression of Generalized Vitiligo. J Interferon Cytokine Res 33: 646-659.
66. Dwivedi M, Laddha NC, Begum R (2013) Correlation of increased MYG1 expression and its promoter polymorphism with disease progression and higher susceptibility in vitiligo patients. J Dermatol Sci 71: 195-202.
67. Dwivedi M, Laddha NC, Mansuri MS, Marfatia YS, Begum R (2013) Association of NLRP1 genetic variants and mRNA overexpression with generalized vitiligo and disease activity in a Gujarat population. Brit J Dermatol 169: 1114-1125
68. Hernanz A, Tato E, De la Fuente M, de Miguel E, Arnalich F (1996) Differential effects of gastrin-releasing peptide, neuropeptide Y, somatostatin and vasoactive intestinal peptide on interleukin-1 beta, interleukin-6 and tumor necrosis factoralpha production by whole blood cells from healthy young and old subjects. J Neuroimmunol 71: 25-30.
69. Ben-Sasson SZ, Hu-Li J, Quiel J, Cauchetaux S, Ratner M, et al. (2009) IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiation. Proc Natl Acad Sci USA 106: 7119-7124.
70. Maliszewski CR, Sato TA, Vanden Bos T, Waugh S, Dower SK, et al. (1990) Cytokine receptors and B cell functions. I. Recombinant soluble receptors specifically inhibit IL-1- and IL-4-induced B cell activities in vitro. J Immunol 144: 3028-3033.
71. Chung Y, Chang SH, Martinez GJ, Yang XO, Nurieva R, et al. (2009) Critical regulation of early Th17 cell differentiation by interleukin-1 signaling. Immunity 30: 576-587.
72. Dwivedi M, Laddha NC, Arora P, Marfatia YS, Begum R (2013) Decreased regulatory T-Cells and CD4+/CD8+ ratio correlate with disease onset and progression in patients with generalized vitiligo. Pigment Cell Melanoma Res 26: 586-591.
73. Laddha NC, Dwivedi M, Mansuri MS, Singh M, Gani AR, et al. (2014) Role of oxidative stress and autoimmunity in onset and progression of vitiligo. Exp Dermatol 23: 352-353.